GMAB News and Press, Genmab A/S From 09/04/23

Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a future medical meeting Genmab and Seagen to engage i...

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK ® (tisotumab vedotin-tftv), compared w...

2023-08-31 05:42:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards ...

2023-08-30 11:17:45 ET Summary Genmab's stock is down 15% since late 2022 highs but the company and its partners continue to execute well. The approval and launch of Epkinly for the treatment of DLBCL is a significant milestone for Genmab and Epkinly has the potential to become on...

2023-08-03 17:58:02 ET Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Judith Klimovsky - Chief Development Officer Anthony M...

2023-08-03 11:06:41 ET Genmab press release ( GMAB ): 1H GAAP EPS of DKK20.61. Revenue of DKK4.2B (+32.9% Y/Y). For further details see: Genmab GAAP EPS of DKK20.61, revenue of DKK4.2B

August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab- bysp ) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody t...

2023-08-02 11:44:06 ET Genmab ( GMAB ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $0.23 and the consensus Revenue Estimate is $600.62M Over the last 3 months, EPS estimates have seen 0 upward re...

2023-07-28 03:14:44 ET Genmab ( GMAB ) expects 34% Y/Y growth in H1 2023 revenue to reach DKK 7.05B, with operating expenses expected to jump 45% to DKK 5.12B. This gives a 10% boost to operating profit, touching DKK 1.93B. Genmab ( GMAB ) also lays down 2023 FY ...

Company Announcement COPENHAGEN , Denmark; July 2 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. ...